The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model
Open Access
- 31 August 2010
- journal article
- Published by American Society for Microbiology in mBio
- Vol. 1 (3)
- https://doi.org/10.1128/mbio.00139-10
Abstract
Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis . Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection model, in which organisms are exposed to clinically relevant drug concentration-time profiles and the impact on bacterial cell kill and resistant subpopulation amplification is determined. In log phase, resistance emergence was observed in all monotherapy regimens and in no combination therapy regimen. No difference was seen in time to a 3-log reduction in the bacterial burden; there was a significant difference in time to resistance emergence ( P = 0.0006). In the NRP experiment, no resistance emergence was seen. There was a significant difference between the monotherapy and combination therapy regimens in time to a 3-log reduction in the bacterial burden ( P = 0.042). The combination is efficacious for suppressing resistant organisms but is antagonistic for cell kill. IMPORTANCE M. tuberculosis infects one-third of the world’s population. Multiresistant organisms have become more frequent, threatening our ability to provide adequate chemotherapy. Moxifloxacin has been seen as an important new agent with the potential to supplant isoniazid or add to the rifampin/isoniazid combination. M. tuberculosis also exists in different physiological states, including the NRP phenotype. We examined the moxifloxacin/rifampin combination in a new in vitro system to allow judgment of how moxifloxacin would interact with rifampin and allow its performance in clinical trials to be placed into perspective. Importantly, the combination suppressed resistance emergence, but at the price of slightly slowing bacterial cell kill. This new combination is a welcome addition to the physician’s armamentarium.Keywords
This publication has 16 references indexed in Scilit:
- Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2009
- Differing Effects of Combination Chemotherapy with Meropenem and Tobramycin on Cell Kill and Suppression of Resistance of Wild-Type Pseudomonas aeruginosa PAO1 and Its Isogenic MexAB Efflux Pump-Overexpressed MutantAntimicrobial Agents and Chemotherapy, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteriaProceedings of the National Academy of Sciences of the United States of America, 2008
- Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous SputumPLoS Medicine, 2008
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Microaerophilic Induction of the Alpha-Crystallin Chaperone Protein Homologue ( hspX ) mRNA of Mycobacterium tuberculosisJournal of Bacteriology, 2001
- Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosisTubercle and Lung Disease, 1998
- Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in miceAntimicrobial Agents and Chemotherapy, 1992
- In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-livesJournal of Antimicrobial Chemotherapy, 1985